Orchid Ventures Past Earnings Performance
Past criteria checks 0/6
There is insufficient data on Orchid Ventures's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2022 |
Recent past performance updates
No updates
Recent updates
In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Orchid Ventures has not provided sufficient past data to assess its track record.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.
Show sectionRevenue & Expenses BreakdownBeta
How Orchid Ventures makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 22 | 1 | -3 | 4 | 0 |
| 31 Dec 21 | 2 | -4 | 4 | 0 |
| 30 Sep 21 | 2 | -3 | 4 | 0 |
| 30 Jun 21 | 4 | -3 | 4 | 0 |
| 31 Mar 21 | 3 | -3 | 3 | 0 |
| 31 Dec 20 | 4 | -2 | 3 | 0 |
| 30 Sep 20 | 3 | -4 | 4 | 0 |
| 30 Jun 20 | 1 | -7 | 5 | 0 |
| 29 Feb 20 | 4 | -10 | 8 | 0 |
| 30 Nov 19 | 5 | -11 | 9 | 0 |
| 31 Aug 19 | 5 | -9 | 8 | 0 |
| 31 May 19 | 6 | -7 | 7 | 0 |
| 28 Feb 19 | 4 | -2 | 4 | 0 |
| 30 Nov 18 | 3 | -2 | 4 | 0 |
| 31 Aug 18 | 3 | -1 | 3 | 0 |
| 31 May 18 | 2 | -2 | 3 | 0 |
Quality Earnings: Insufficient data to determine if ORVR.F has high quality earnings.
Growing Profit Margin: Insufficient data to determine if ORVR.F's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if ORVR.F's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare ORVR.F's past year earnings growth to its 5-year average.
Earnings vs Industry: Insufficient data to determine if ORVR.F's earnings growth over the past year exceeded the Pharmaceuticals industry average.
Return on Equity
High ROE: ORVR.F has a negative Return on Equity (0%), as it is currently unprofitable.